Semaglutide is the established GLP-1 weight-loss and diabetes drug; mazdutide is an investigational dual agonist that adds glucagon-receptor activity to the GLP-1 effect. The comparison is really between a proven, approved single-hormone drug and an emerging multi-hormone candidate still working through its evidence.
At a glance
| Semaglutide | Mazdutide | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 + glucagon dual agonist (oxyntomodulin analog) |
| Brand names | Ozempic, Wegovy, Rybelsus | Investigational (no US brand) |
| Extra mechanism | None — single receptor | Glucagon activity may raise energy expenditure |
| FDA status | Approved (T2D & weight management) | Not FDA-approved; in development |
| Evidence base | Large completed trials (STEP, SUSTAIN) | Emerging trial data, not yet mature |
| Route | Once-weekly injection; oral option | Once-weekly injection (in trials) |
The bottom line
Semaglutide is a known quantity: FDA-approved, backed by large completed trials, and widely used. Mazdutide is an interesting next-generation candidate whose added glucagon activity could, in theory, boost energy expenditure on top of appetite suppression — but it is still investigational, and its benefit-and-risk balance is not yet established to the same standard. For now this is a comparison between a proven medicine and a promising work in progress; anyone weighing them should recognize that only one has completed the bar of approval.
Frequently asked questions
Is mazdutide better than semaglutide?
It's too early to say. Mazdutide adds glucagon-receptor activity that may increase energy expenditure alongside GLP-1 appetite suppression, but it is still investigational, while semaglutide is FDA-approved with large completed trials. Mature head-to-head evidence in people is what would settle the question.
What is the difference between semaglutide and mazdutide?
Semaglutide activates a single receptor (GLP-1); mazdutide is a dual agonist that activates both the GLP-1 and glucagon receptors. Semaglutide is approved and widely used, whereas mazdutide is still in clinical development.
Is mazdutide FDA-approved?
No. Mazdutide is an investigational drug still in development and is not FDA-approved. Semaglutide, by contrast, is FDA-approved for type 2 diabetes and chronic weight management.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study
- Ji L, Gao L, Jiang H, et al. Safety and efficacy of the GLP-1/glucagon dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity: a phase 1b trial. eClinicalMedicine. 2022. Peer-reviewed study
- Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023. Peer-reviewed study
- Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. Peer-reviewed study
- Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026. Peer-reviewed study
- Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024. Peer-reviewed study
- Shirley M. Mazdutide: First Approval. Drugs. 2025. Peer-reviewed study